medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2011, Número 2

<< Anterior Siguiente >>

Residente 2011; 6 (2)


Medicina tradicional: estudios preclínicos de plantas con propiedades ansiolíticas

Sollozo-Dupont MI, Estrada CE, López-Rubalcava C

Idioma: Español
Referencias bibliográficas: 55
Paginas: 78-84
Archivo PDF: 66.99 Kb.


RESUMEN

En el presente trabajo se describe un panorama general sobre la ansiedad patológica, el impacto que tiene en la sociedad moderna y la tendencia actual por la búsqueda de alternativas terapéuticas basadas en productos naturales que tengan un mínimo de efectos colaterales. Además, se hace una revisión de ensayos preclínicos que se han realizado para estudiar la actividad y mecanismo de acción de plantas con propiedades ansiolíticas más comunes. Finalmente, se describe cómo se estudia este padecimiento utilizando modelos animales y se reflexiona sobre la importancia de usar en la terapéutica, compuestos bien estandarizados, cuya seguridad y eficacia se han mostrado experimentalmente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kaplan ME, DuPont RL. Benzodiazepines and anxiety disorders: a review for the practicing physician. Curr Med Res Opin 2005; 21(6): 941-950.

  2. Ballenger J. Comorbidity of panic and depression: implications for clinical management. International Clinical Psychopharmacology 1998; 13(4): S13-S17.

  3. Berenzon GS, Alanís NS, Saavedra SN. El uso de las terapias alternativas y complementarias en población mexicana con trastornos depresivos y de ansiedad: Resultados de una encuesta en la Ciudad de México Salud Mental 2009; 32(2): 107-115.

  4. Organización Mundial de la Salud (OMS): Estrategia de la OMS sobre medicina tradicional 2002-2005. WHO/EDM/TRM 2002.1. Ginebra: Programa de medicina tradicional. OMS, 2002.

  5. Organización Mundial de la Salud (OMS): Pautas generales para las metodologías de investigación y evaluación de la medicina tradicional WHO/EDM/TRM 72000.1. Ginebra OMS 2000.

  6. Bouton ME, Mineka S, Barlow DH. A modern’s leraning theory on the etiology of panic disorder Psychological Review 2001; 108(1): 4-32.

  7. Kaplan, Sadock’s: Comprehensive Textbook of Psychiatry Lippincott Williams & Wilkins, 2002.

  8. Rodríguez-Landa JF, Contreras CM. Algunos datos recientes sobre la fisiopatología de los trastornos de ansiedad. Revista biomed 1998; 9(3): 181-191.

  9. Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3a-hydroxy-5a[b]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 1991; 561(1): 157-163.

  10. Itoi K, Sugimoto N. The brainstem noradrenergic systems in stress, anxiety and depression. J Neuroendocrinol 2010; 22(5): 355-361.

  11. Kalk NJ, Nutt DJ, Lingford-Hughes AR. The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies. J Psychopharmacol 2011; 25(1): 3-1

  12. Goddard AW, Shekhar A, Whiteman AF, McDougle CJ. Serotoninergic mechanisims in the treatment of obsessive-compulsive disorder. Drug Discov Today 2008; 13(2): 325-332.

  13. Shishkina GT. Neuroadaptive changes in brain during selective serotonin reuptake inhibitors action. Ross Fiziol Zh Im I M Sechenova 2007; 93(3): 1245-1251.

  14. LeDoux JE. Emotion: clues from the brain. Ann Rev Psychol 1995; 46(2): 209-235.

  15. Rodgers RJ. Animal models of anxiety: where next? Behav Pharmacol 1997; 8(6-7): 477-496.

  16. Treit D. Animal models for the study of anti-anxiety agents: A review. Neurosci Biobehav Rev 1985; 9(2): 203-222.

  17. Willner P. Behavioural models in psychopharmacology. Behavioural Models in Psychopharmacology: the Theoretical, Industrial and Clinical Perspectives. Cambridge University Press, 1991.

  18. Walsh RN, Cummins RA. The open-field test: a critical review. Psychol 1976; 83(3): 482-504.

  19. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology 1971; 21(1): 1-7.

  20. Bruneton J. Farmacognosia. Fitoquímica. Plantas Medicinales. Acribia, 2001.

  21. Speroni E, Minghetti A. Neuropharmacological activity of extracts from Passiflora incarnata. Planta Med 1988; 54 (6): 488-491.

  22. Dhawan K, Kumar S, Sharma A. Anxiolityc activity of aerial and underground parts of Passiflora incarnate. Fitoterapia 2001; 72(5): 922-926.

  23. EMEA. Community herbal monograph on Passiflora incarnata L., herba.http://www.emea.europa.eu/pdfs/human/hmpc/passiflorae_herba/23096206enfin.pdf., 2007.

  24. Phillipson JD. Phytochemistry and pharmacognosy. Phytochemistry 2007; 68(22-24): 2960–2972.

  25. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonist of the 5-HT5A receptor in vitro. Mol Brain Res 2005; 138(2): 191-197.

  26. Müller CE, Schumacher B, Brattström A, Abourashed EA, Koe tter U. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptor. Life Sci 2002; 71(16): 1939-1949.

  27. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. J Am Med Assoc 1998; 280(18): 1566-1567.

  28. Jamieson DD, Duffield PH, Cheng D, Duffield AM. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum). Arch Int Pharmacodyn 1989; 301(3): 66-80.

  29. Shinomiya K, Inoue T, Utsu Y, Tokunaga S, Masuoka T, Ohmori A, Kamei C. Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. Psychopharmacology 2005; 180(5): 564-569.

  30. Grunze H, Langosch J, Schirrmacher K, Bingmann D, Von Wegerer J, Walden J. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar to established mood stabilizers-a review. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25(8): 1555-1570.

  31. Denham A, McIntyre M, Whitehouse J. Kava-the unfolding story: report on a work-in-progress. J Altern Complement Med 2002; 8(3): 237-263.

  32. Norton AS, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31(1): 89-97.

  33. Coleta M, Campos MG, Cotrim MD, Proenca da Cunha A. Comparative evaluation of Melissa officinalis L, Tilia europaea L, Passiflora edulis Sims and Hypericum perforatum L in the elevated plus maze anxiety test. Pharmacopsychiatry 2001, 34: S20-S21.

  34. Soulimani R, Fleurentin J, Mortier F, Misslin R, Derrieu G, Pelt JM. Neurotropic action of the hydroalcoholic extract of Melissa officinalis in the mouse. Planta Medica 1991; 57(1): 105-109.

  35. Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can Physiol Pharmacol 2007; 85(9): 933-942.

  36. Pérez-Ortega G, Guevara-Fefer P, Chávez M, Herrera J, Martínez A, Martínez AL, González-Trujano ME. Sedative and anxiolytic efficacy of Tilia americana var. mexicana inflorescences used traditionally by communities of State of Michoacan, Mexico. J Ethnopharmacol 2008;116(3): 461-468.

  37. Aguirre-Hernández E, Martínez AL, González-Trujano ME, Moreno J, Vibrans H, Soto-Hernández M. Pharmacological evaluation of the anxiolytic and sedative effects of Tilia americana L. var. mexicana in mice. J Ethnopharmacol 2007, 109(1): 140-145.

  38. Vanaclocha B, Cañigueral S. Fitoterapia. Vademécum de prescripción. Masson, 2003.

  39. Andronis C, Sharma A, Virvilis V, Deftereos S, Persidis A. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 2011: 1-5.

  40. Eisenberg DM, Davis RB, Ettner SL, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. J Am Med Assoc 1998; 280(18): 1569-1575.

  41. Barnes J, Anderson LA, Phillipson JD. Herbal Medicines. A guide for Healthcare Professionals Pharmaceutical Press, 2007.

  42. Chen W, Luo YF, Liu JP. Topical herbal medicine for treatment of diabetic peripheral neuropathy: a systematic review of randomized controlled trials. Forsch Komplementmed 2011; 18(3): 134-145.

  43. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: Prevalence, cost and pattems of use. N Engl J Med 1993; 328(4): 246-252.

  44. Kumar JK, Bhatnagar SP. Risking alternative and complementary medicine in the name of standardization. J. Alternative Complementary Med 2006; 12(5): 419-420.

  45. Zanoli P, Zavatti M. Pharmacognostic and pharmacological profile of Humulus lupulus L. J Ethnopharmacol 2008; 116(3): 383-396.

  46. Herrera-Ruíz M, González-Cortazar M, Jiménez-Ferrer E, Zamilpa A, Alvarez L, Ramírez G, Tortoriello J. Anxiolytic effect of natural galphimines from Galphimia glauca and their chemical derivatives. J Nat Prod 2006; 69(1): 59-61.

  47. Prieto-Gómez B, Tortoriello J, Vázquez-Alvarez A, Reyes-Vázquez C. Galphimine B modulates synaptic transmission on dopaminergic ventral tegmental area neurons. Planta Med 2003; 69(1): 38-43.

  48. Wijeweera P, Arnason JT, Koszycki D, Merali Z. Evaluation of anxiolytic properties of Gotukola--(Centella asiatica) extracts and asiaticoside in rat behavioral models. Phytomedicine 2006; 13(9-10): 668-676.

  49. Gohil KJ, Patel JA, Gajjar AK. Pharmacological Review on Centella asiatica: A Potential Herbal Cure-all. Indian J Pharm Sci 2010; 72(5): 546-556.

  50. López-Rublcava C, Piña-Medina B, Estrada-Reyes R, Heinze G, Martínez-Vázquez M. Anxiolytic-like actions of the hexane extract from leaves of Annona cherimolia in two anxiety paradigms: Possible involvement of the GABA/benzodiazepine receptor complex. Life Sciences 2006; 78(7): 730-737.

  51. Peng WH, Hsieh MT, Lee YS, Lin YC, Liao J. Anxiolytic effect of seed of Ziziphus jujuba in mouse models of anxiety. Journal of Ethnophamacology 2000; 72(3): 435-441.

  52. Cao Y, Chu Q, Ye J. Determination of hydroxyl radical by capillary electrophoresis and studies on hydroxyl radical scavenging activities of Chinese herbs. Analytical and Bioanalytical Chemistry 2003; 376(7): 691-395.

  53. Zhang ZJ, Qian YH, Hu HT, Yang J, Yang GD. The herbal medicine Dipsacus asper wall extract reduces the cognitive deficits and overexpression of beta-amyloid protein induced by aluminum exposure Life Sciences 2003; 73(19): 2443-2454.

  54. Vincieri FF. An approach to the study of the biological activity of Eschscholtzia californica Cham. Pharmacol Res Commun 1988; 20(5): 41-44.

  55. Estrada-Reyes R, López-Rublcava C, Rocha L, Heinze G, González Esquinca AR, Martínez-Vázquez M. Anxiolytic-like and sedative actions of Rollinia mucosa: Possible involvement of the GABA/benzodiazepine receptor complex. Pharmaceutical Biology 2010; 48(1): 70-75.




2020     |     www.medigraphic.com